ストックスクリーナーアプリを入手
22.37
7.22%
-1.74
アフターアワーズ：
22.92
0.55
+2.46%
前日終値:
$24.11
開ける：
$23.97
24時間の取引高:
1.91M
Relative Volume:
0.81
時価総額：
$1.39B
収益：
$14.34M
当期純損益:
$-199.00M
株価収益率:
-5.7066
EPS:
-3.92
ネットキャッシュフロー:
$-183.51M
1週間 パフォーマンス:
-8.77%
1か月 パフォーマンス:
-2.91%
6か月 パフォーマンス:
+56.43%
1年 パフォーマンス:
+68.20%
1日の値動き範囲:
$22.28
$24.39
1週間の範囲:
$22.28
$28.03
52週間の値動き範囲:
$7.76
$71.50
Uniqure N V Stock (QURE) Company Profile
Compare QURE vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
QURE
Uniqure N V
|
22.37 | 1.50B | 14.34M | -199.00M | -183.51M | -3.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Uniqure N V Stock (QURE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-28 | 開始されました | Barclays | Equal Weight |
| 2025-11-04 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2025-08-14 | アップグレード | Mizuho | Neutral → Outperform |
| 2025-04-01 | 再開されました | Chardan Capital Markets | Buy |
| 2024-12-10 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2024-10-10 | 再開されました | Raymond James | Outperform |
| 2024-02-29 | ダウングレード | Goldman | Buy → Neutral |
| 2023-12-19 | ダウングレード | Mizuho | Buy → Neutral |
| 2022-03-17 | アップグレード | UBS | Neutral → Buy |
| 2021-06-15 | 開始されました | BTIG Research | Buy |
| 2021-05-21 | 開始されました | UBS | Neutral |
| 2021-04-26 | 再開されました | Credit Suisse | Outperform |
| 2021-04-01 | アップグレード | Mizuho | Neutral → Buy |
| 2021-01-07 | アップグレード | Guggenheim | Neutral → Buy |
| 2020-11-24 | 開始されました | H.C. Wainwright | Buy |
| 2020-11-11 | 開始されました | Berenberg | Buy |
| 2020-11-09 | 開始されました | Jefferies | Buy |
| 2020-11-04 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-10-23 | 開始されました | RBC Capital Mkts | Outperform |
| 2020-08-25 | 開始されました | Raymond James | Strong Buy |
| 2020-07-31 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2020-06-25 | ダウングレード | Mizuho | Buy → Neutral |
| 2020-06-25 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2020-06-25 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2019-12-03 | 開始されました | Cowen | Outperform |
| 2019-12-03 | 開始されました | Goldman | Buy |
| 2019-11-05 | 開始されました | Credit Suisse | Outperform |
| 2019-10-11 | 開始されました | Stifel | Buy |
| 2019-09-25 | 開始されました | Bernstein | Outperform |
| 2019-09-12 | 開始されました | Mizuho | Buy |
| 2019-07-30 | ダウングレード | Guggenheim | Buy → Neutral |
| 2019-07-08 | 繰り返されました | Cantor Fitzgerald | Overweight |
| 2019-04-12 | 開始されました | Piper Jaffray | Overweight |
| 2019-03-29 | 開始されました | Robert W. Baird | Outperform |
すべてを表示
Uniqure N V (QURE) 最新ニュース
Investor Alert: A Securities Fraud Class Action Lawsuit Has Been Filed Against uniQure N.V. (QURE)Contact Kessler Topaz Meltzer & Check, LLP - PR Newswire
uniQure Shareholder Alert: ClaimsFiler Reminds Investors - GlobeNewswire
UNIQURE N.V. (QURE) INVESTOR ALERT Investors With Large Losses in uniQure N.V. Should Contact ... - Bluefield Daily Telegraph
UNIQURE N.V. (QURE) INVESTOR ALERT Investors With Large - GlobeNewswire
QURE DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds uniQure (QURE) Investors of Securities Class Action Deadline on April 13, 2026 - PR Newswire
UniQure N.V. Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your Rights – QURE - marketscreener.com
uniQure Faces Class Action Lawsuit Reminder for Investors - Intellectia AI
QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit with the Schall Law Firm - Business Wire
Securities Class Action Filed Against uniQURE N.V. – Investors Encouraged to Contact Kirby McInerney LLP - FinancialContent
Class Action Announcement for uniQure N.V. (QURE): Kessler - GlobeNewswire
Rosen Law Firm Urges uniQure N.V. (NASDAQ: QURE) Stockholders with Large Losses to Contact the Firm - pharmiweb.com
Rosen Law Firm Urges uniQure N.V. (NASDAQ: QURE) Stockholders with Large Losses to Contact the Firm for Information About Their Rights - Bluefield Daily Telegraph
Bronstein, Gewirtz & Grossman LLC Urges uniQure N.V. Investors to Act: Class Action Filed Alleging Investor Harm - GlobeNewswire
INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of - GlobeNewswire
uniQure N.V. Securities Fraud Class Action Result of FDA Approval Delay and 49% Stock DeclineInvestors May Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC - The AI Journal
Can uniQure N.V. ride the EV wave2025 Volatility Report & Reliable Volume Spike Trade Alerts - mfd.ru
UniQure Investor Sues Over Delayed Huntington’s Drug Application - Bloomberg Law News
Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the uniQure N.V. Securities Class Action Lawsuit - The AI Journal
UNIQURE ALERT: Bragar Eagel & Squire, P.C. Announces that a - GlobeNewswire
uniQure N.V. (QURE) Investors: Kessler Topaz Meltzer & Check, LLP Announces That the Firm Has Filed a Securities Fraud Class Action Lawsuit Against uniQure N.V. and Encourages Investors to Contact the Firm - The AI Journal
Weekly Recap: Can uniQure NV ride the EV wavePortfolio Return Report & Reliable Intraday Trade Plans - baoquankhu1.vn
uniQure (NASDAQ:QURE) Earns Buy Rating from HC Wainwright - MarketBeat
Risk Hedge: Is BlackRock Multi Sector Income Trust benefiting from innovation trendsJuly 2025 Summary & Long-Term Growth Plans - baoquankhu1.vn
Diamond Hill Capital Management Inc. Sells 49,320 Shares of uniQure N.V. $QURE - MarketBeat
How Early AMT-191 Gene Therapy Signals Will Impact uniQure (QURE) Investors - simplywall.st
Discipline and Rules-Based Execution in QURE Response - Stock Traders Daily
uniQure reports promising data from Fabry disease gene therapy trial By Investing.com - Investing.com Nigeria
UniQure's AMT-191 Sustains Key Enzyme Activity In Fabry Disease In Phase I/IIa Trial; Stock Up - Nasdaq
Uniqure stock rises after AMT-191 gene therapy shows promising Fabry results - Investing.com Nigeria
Uniqure stock rises after AMT-191 gene therapy shows promising Fabry results By Investing.com - Investing.com South Africa
uniQure reports promising data from Fabry disease gene therapy trial - Investing.com
uniQure (QURE) Shares Promising Data on Gene Therapy for Fabry D - GuruFocus
uniQure Announces Updated Preliminary AMT-191 Phase I/IIa Data Showing Sustained Increases in α-Gal A Enzyme Activity in Patients with Fabry Disease - The Manila Times
uniQure Announces Updated Preliminary AMT-191 Phase I/IIa - GlobeNewswire
uniQure (NASDAQ:QURE) Stock Price Up 8.6%What's Next? - MarketBeat
Here’s Why uniQure (QURE) Declined in Q4 - Yahoo Finance
Aug Opening: Why is uniQure NV stock going downWeekly Risk Summary & Fast Gain Stock Trading Tips - baoquankhu1.vn
Stock Recap: Is uniQure NV stock risky to hold nowQuarterly Earnings Report & Expert Approved Trade Ideas - baoquankhu1.vn
QURE Investigation: Kessler Topaz Meltzer & Check, LLP Encourage - GuruFocus
Update Recap: Will uniQure NV benefit from geopolitical trendsJuly 2025 Chart Watch & Safe Capital Allocation Plans - baoquankhu1.vn
QURE Investigation: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ - marketscreener.com
QURE Investigation: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm - PR Newswire
Aug Swings: Can uniQure NV continue delivering strong returnsInflation Watch & Verified Swing Trading Watchlists - baoquankhu1.vn
Privium Fund Management B.V. Sells 61,486 Shares of uniQure N.V. $QURE - MarketBeat
UniQure N.V. (QURE) Stock Analysis: A Biotech Player With 127.68% Potential Upside - DirectorsTalk Interviews
QURE Investigation Alert: Kessler Topaz Meltzer & Check, - GlobeNewswire
Geopolitics Watch: Can uniQure NV continue delivering strong returnsQuarterly Portfolio Review & Fast Exit/Entry Strategy Plans - baoquankhu1.vn
uniQure (NASDAQ:QURE) Stock Rating Upgraded by Barclays - MarketBeat
Barclays Downgrades UniQure NV(QURE.US) to Hold Rating, Raises Target Price to $31 - 富途牛牛
Barclays Initiates Coverage of uniQure N.V. (QURE) with Equal-Weight Recommendation - Nasdaq
What Analysts Are Saying About uniQure Stock - Benzinga
Uniqure N V (QURE) 財務データ
収益
当期純利益
現金流量
EPS
Uniqure N V (QURE) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Gut Robert | Director |
Jan 12 '26 |
Sale |
24.62 |
25,613 |
630,483 |
32,342 |
| Kaye Jack | Director |
Jan 09 '26 |
Option Exercise |
19.39 |
6,390 |
123,902 |
26,829 |
| Kaye Jack | Director |
Jan 09 '26 |
Sale |
27.28 |
6,390 |
174,319 |
20,439 |
1.24%
0.19%
大文字化:
|
ボリューム (24 時間):